Investigating ghrelin and its isoforms in eating disorders: a network meta-analysis
Abstract
BACKGROUND
Eating disorders (EDs) are serious psychiatric conditions disorders characterized by impairments in appetite regulation and energy balance. Among the biological factors implicated in their pathophysiology, the orexigenic hormone ghrelin and its isoforms (acyl-ghrelin [AG] and desacyl-ghrelin [DAG]) have been shown to play a key role in appetite regulation and may contribute to the maintenance of disordered eating behaviors.
METHODS
A systematic review of existing literature and meta-analysis were conducted, including 80 studies examining fasting blood levels of ghrelin, AG, and DAG across various ED diagnostic categories and healthy controls (HC), including also individuals with recovered AN (AN-rec). A network meta-analysis (NMA) approach through a multilevel linear mixed-effects meta-regression model was employed to estimate hormone levels, while accounting for covariates such as body mass index (BMI), sex, blood composition and assay type.
RESULTS
Ghrelin levels were significantly elevated in individuals with anorexia nervosa (AN) and bulimia nervosa (BN) when compared to HC, while binge eating disorder (BED) was associated with lower ghrelin levels than individuals with BN and HC. AG and DAG levels were significantly elevated in individuals with AN compared to HC, and confirmed higher in AN-rec if compared to HC. No significant differences in ghrelin, AG and DAG levels were observed for avoidant/restrictive food intake disorder (ARFID).
CONCLUSIONS
This…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.